Plain-English translation of NCT06299514 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a newer pacemaker device combined with a heart procedure works better than taking medications alone for people with atrial fibrillation (an irregular heartbeat) and heart failure. Half of the participants will receive guideline-directed medications to slow their heart rate, while the other half will receive a special pacemaker device called conduction system pacing (CSP) along with a procedure to ablate (intentionally damage) part of the heart's electrical system. The goal is to see which approach helps people feel better and live longer.
Many people with atrial fibrillation struggle to tolerate the medications needed to control their heart rate, and those medications can cause troublesome side effects. This trial exists to find out whether a pacemaker-based approach might be a better option for people whose irregular heartbeat and heart failure aren't well-controlled by drugs alone.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the group, you will continue taking heart failure and heart rate control medications as recommended by your doctor. If you are assigned to the pacemaker group, you will undergo a procedure to have a conduction system pacing device implanted within 10 days of enrollment, followed by a second procedure within 4 weeks to ablate part of your heart's electrical system. Either way, you will be followed by the research team over time to see how well each approach works for your symptoms and overall health.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Canada